Vedolizumab demonstrated dose-proportional pharmacokinetics and maximally saturated α(4) β(7) receptors over the tested dose range. Multiple dosing up to 10 mg/kg was well tolerated. Over the course of follow-up a greater proportion of patients treated with vedolizumab were in clinical response than those who were assigned to placebo.

No abstract

tain remission in Crohn disease is an unmet medical need. Although formulations of 5-aminosalicylic acid agents remain widely used for this purpose, strong evidence exists that they are not effec-tive. 1 Immunosuppressive agents such as purine antimetabolites, 2,3 methotrexate, 4 and tumor necrosis factor ␣ antagonists 5-8 are moderately effective for maintaining remission; however, their use is associated with an increased risk of infection. 9-11 Therefore, development of a safe, inexpensive, and effective orally administered agent is a research priority.Omega-3 free fatty acids are antiinflammatorysubstancesfoundinmarine fishthathaveseveralhealthbenefits.These compounds have been used to treat inflammatorydisorderssuchasrheumatoid See also Patient Page.

No abstract